ENTA Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 4.81%, SMA50 2.94%, SMA200 39.67%). The stock’s 14-day RSI is 57.61 (neutral), while the ATR of 0.78 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -15.98% below its high and over 252.32% above its low. Average 10-day trading volume of 249.30 thousand shares is slightly above the 3-month average of 213.12 thousand, indicating heightened recent market interest.

Enanta Pharmaceuticals, Inc. generated EPS of -$3.20 over the past year. Five-year average earnings growth is -16.17%. Wall Street analysts project EPS growth of 17.2% annually over the next five years. The latest quarter delivered EPS of -$0.67. The next quarter is forecast at -$0.56. Next year's EPS is expected at $5.54. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $28.00 to $12.00. The high target offers 99.71% upside. The low target suggests -14.41% downside. The mean target is $19.50. This offers 39.09% upside. Enanta Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended August 10, 2026, missed forecasts by 31.5%. The prior quarter beat by -2.17%. Over the last six quarters, Apple has recorded several small beats. These include 1.92% in May 12, 2025.

Enanta Pharmaceuticals, Inc. has 29.13 million shares outstanding. The public float is 21.42 million shares, elevated short interest at 10.65% of float. This equals 2.59 million shares. The short ratio is 14.9 days. Institutional investors hold 97.34% of the float. Insiders own 4.68%. Luly Jay R. holds 858.03 thousand shares, Or Yat Sun has 371.39 thousand shares and MELLETT PAUL J has 91.71 thousand shares.

Enanta Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$7.91. This means the shares are trading below this model’s fair value.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) closed at $14.02 USD, losing -$0.07 (-0.50%) from the previous close of $14.09. The stock is currently mid-range between its 52-week high and low $7.05 and $17.15. With a market capitalization of about $407.68 million, Enanta Pharmaceuticals, Inc. is classified as a small-cap and shows market-like volatility (beta ~0.93). Key stats such as the average daily volume over the past year has been around 213.68 thousand shares, in line with its 52-week average. Headquartered in Watertown, MA, Enanta Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jay R. Luly, the company employs approximately 120 people and listed since March 21, 2013. Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions.

Enanta Pharmaceuticals, Inc. trades at a P/E ratio of -5.85, slightly below the S&P 500 average, with a price-to-sales ratio of 6.29 and a price-to-book ratio of 4.06 trading at moderately above to book value. The P/FCF stands at -11.11, also below market averages.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shares are down -20.8% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Enanta Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -5.85. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $44.31, suggesting 216.05% upside. Our AI forecast model points to short-term strength (2.43% over two weeks), a medium-term rise (57.13% over three months), and a longer-term gain (85.73% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Enanta Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.43%, with price expected at $14.36 by September 17, 2026, within a range of $13.95 to $14.76 3-Month Outlook: Projected rise of 57.13%, reaching $22.03 by December 01, 2026, with a range of $21.45 to $22.52. 1-Year Outlook: Projected gain of 85.73%, with price at $26.04 by September 03, 2027, within a range of $16.04 to $35.42.